Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)

https://doi.org/10.20996/1819-6446-2011-7-4-468-472

Full Text:

Abstract

Pharmacotherapy optimization in patients with arterial hypertension and gout is very important. Achievement of the target blood pressure levels is possible with the use of combinations of effective antihypertensive drugs with neutral metabolic profile and safety, in particular a combination of valsartan, amlodipine and aliskiren. Clinical case of this combination use in patient with arterial hypertension and gout is presented.

About the Authors

O. V. Dralova
I.M. Setchenov First Moscow State Medical University.
Russian Federation


M. L. Maksimov
I.M. Setchenov First Moscow State Medical University.
Russian Federation


References

1. Vazguez-Mellado J., Garsia C.G., Vazguez S.G. et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004; 10 (3):105–109.

2. Eliseev M.S., Barskova V.G., Nassonova V.A., Nassonov E.L. Insulin resistance syndrome in patients with gout and its influence on uric acid concentration and severity of arthritis. Ann Rheum Dis 2006; 65 (Suppl II): 432.

3. Choi H.K., Ford E.S., Li С., Curhan G. Prevalence of the Metabolic Syndrome in Patients With Gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57:109-115.

4. Høieggen A., Alderman M.H., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65(3): 1041-1049.

5. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17(5–6): 397–414.

6. Kobalava Zh.D., Tolkacheva V.V. Uric acid is a key link cardiorenal continuum? Part I. Klinicheskaya farmakologiya i terapiya 2003; 12: 15–19. Russian (Кобалава Ж.Д., Толкачева В.В. Мочевая кислота — ключевое связующее звено кардиоренального континуума? Часть I. Клиническая фармакология и терапия 2003; 12: 15–19).

7. Perlstein T.S., Gumieniak O., Hopkins P.N., et al. Uric acid and the state of the intrarenal renin–angiotensin system in humans. Kidney Int 2004; 66:1465–1470.

8. Takahashi S., Moriwaki Y., YamamotoT. et al. Effects of combination treatment using anti–hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572–575.

9. Taylor W. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia. Clin med 2002; 80(2): 77–78.

10. Mychka V.B., Blinova N.V., Chazova I.E. Effective antihypertensive therapy in patients with metabolic syndrome. Sistemnye gipertenzii 2010; 3:71-75. Russian (Мычка В.Б., Блинова Н.В., Чазова И.Е.Эффективная антигипертензивная терапия у больных с метаболическим синдромом. Системные гипертензии 2010; 3:71-75).

11. Karpov Yu.A., Chazova I.E., Vigdorchik A.V. Efficacy and security of a fixed combination of amlodipine and valsartan in the treatment of hypertension in clinical practice: results of the Russian observational study EKSTRA-2. Sistemnye gipertenzii 2010;4:14-21. Russian (Карпов Ю.А., Чазова И.Е., Вигдорчик А.В. Эфективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии 2010;4:14-21).

12. Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Resistant and uncontrolled hypertension in the Russian Federation: epidemiological characteristics and treatment approaches (Russian Register of uncontrolled and resistant hypertension REGATTA "Resistant Arterial Hypertension"). Kardiologicheskiy vesnik 2011; VI (1): 40-48. Russian (Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Резистентная и неконтролируемая артериальная гипертония в Российской Федерации: эпидемиологическая характеристика и подходы к лечению (Российский регистр неконтролируемой и резистентной артериальной гипертонии РЕГАТА «Резистентная Гипертония Артериальная»). Кардиологический вестник 2011; VI (1): 40-48).

13. Jordan J., Engeli S., Boye S.W. et al. Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension. Hypertension 2007; 49(5): 1047-1055.

14. Abbott R.D., Brand F.N., Kannel W.B., Castelli W.P. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988; 41:237–242.


For citation:


Dralova O.V., Maksimov M.L. COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT). Rational Pharmacotherapy in Cardiology. 2011;7(4):468-472. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-4-468-472

Views: 420


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)